Diffuse panbronchiolitis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 21, Issue 2, 2004, Pages 94-104

  Poletti, Venerino ^a   Chilosi, Marco ^b   Casoni, Gianluca ^a   Colby, Thomas V ^c  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c MAYO CLINIC   (United States)

Author keywords

Diffuse panbronchiolitis; Erythromycin; Foamy Macrophages; HLA haplotype; Macrolides

Indexed keywords

BRONCHODILATING AGENT; CLARITHROMYCIN; CYTOKINE; ERYTHROMYCIN; INTERLEUKIN 8; MACROLIDE; MACROPHAGE INFLAMMATORY PROTEIN 1; ROXITHROMYCIN;

ANTIINFLAMMATORY ACTIVITY; BACTERIUM ISOLATION; BRONCHIECTASIS; BRONCHIOLITIS; DIFFUSE PANBRONCHIOLITIS; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOREGULATION; JAPAN; LONG TERM CARE; MORTALITY; NEUTROPHIL; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SINUSITIS; T LYMPHOCYTE;

BRONCHIOLITIS; HUMANS; JAPAN;

EID: 3242659091     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Homma H, Yamanaka A, Tanimoto S, et al: Diffuse panbronchiolitis: a disease of the transitional zone of the lung. Chest 1983; 83: 63-9.
2. Iwata M, Sato A, Colby TV: Diffuse panbronchiolitis. In: Epler GR (ed): Diseases of the bronchioles. New York: Raven press 1994: 153-79.
3. Yamanaka A, Saiki S, Tamura S, Saito K: Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis. Naika 1969; 23: 442-51.
4. Sugiyama Y: Diffuse panbronchiolitis. Clin Chest Med 1993; 14: 765-72.
5. Tsang KWT: Diffuse panbronchiolitis: diagnosis and treatment. Clin Puhn Med 2000; 7: 245-52.
6. Homma H: Diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1975; 13: 383-95.
7. Izumi T, Doi O, Nobechi A, et al: Nation-wide survey of diffuse panbronchiolitis. Annual Report on the study of interstitial lung disease in 1982. Grant-in Aid from the Ministry of Health and Welfare of Japan, Tokyo, Japan 1983: 3-41.
8. Chu YC, Yeh SZ, Chen CL, Chen CY, Chang CY, Chiang CD: Diffuse panbronchiolitis: report of a case. J Formosan Med Assoc 1992; 91: 912-5.
9. Kim YW, Han SK, Shim YS, et al: The first report of diffuse panbronchiolitis in Korea: five case reports. Intern Med 1992, 31: 695-701.
10. Hu H, Liu Y, Cai Z, Chen L: A case of diffuse panbronchiolitis. Chin Med J 1996; 109: 949-52.
11. Zainudin BM, Roslina AM, Fadilah SA, Sufarlan AW, Isa MR: A report of the first three cases of diffuse panbronchiolitis in Malaysia. Med J Malaysia 1996; 51: 136-40.
12. Tsang KW, Ooi CG, Ip MS, et al: Clinical profiles of Chinese patients with diffuse panbronchiolitis. Thorax 1998; 53: 274-80.
13. Chantarotorn S, Palwatwichai A, Vattanathum A, Tantamacharik D: Diffuse panbronchiolitis, the first case reports in Thailand. J Med Assoc Thai 1999; 82: 833-8.
14. Poh SC, Wang YT, Wang WY: Diffuse panbronchiolitis-a case report. Singapore Med J 2001; 42: 271-4.
15. Desai SJ, Gephartd GN, Stoller JK: Diffuse panbronchiolitis preceding ulcerative colitis. Chest 1989; 95: 1342-4.
16. Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L: Diffuse panbronchiolitis observed in an Italian. Chest 1990; 98: 515-6.
17. Randhawa P, Hoagland MH, Yousem SA: Diffuse panbronchiolitis in North America. Report of three cases and of the literature. Am J Surg Pathol 1991; 15: 43-7.
18. Tredaniel J, Cazals-Hatem D, Zalcman G, d'Agay MF, Capron F: Diffuse panbronchiolitis: efficacy of low-dose erythromycin. Respir Med 1994; 88: 479-80.
19. Homer RJ, Khoo L, Smith GJ: Diffuse panbronchiolitis in a Hispanic man with travel history to Japan. Chest 1995; 107: 1176-8.
20. Fitzgerald JE, King TE Jr, Lynch DA, Tuder RM, Schwarz MI: Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med 1996; 154: 497-503.
21. Brugiere O, Milleron B, Antoine M, Carette MF, Philippe C, Mayaud C: Diffuse panbronchiolitis in an Asian immigrant. Thorax 1996; 51: 1065-7.
22. Zompatori M, Poletti V: Diffuse panbronchiolitis. An Italian experience. Radiol Med 1997; 94: 680-2.
23. Fisher MS Jr, Rush WL, Rosado-de-Christenson ML, et al: Diffuse panbronchiolitis: histologic diagnosis in unsuspected cases involving North American residents of Asian descent. Arch Pathol Lab Med 1998; 122: 156-60.
24. Schulte W, Szrepka A, Bauer PC, Guzman J, Costabel U: Diffuse panbronchiolitis. A rare differential diagnosis of chronic obstructive lung disease. Dtsch Med Wochenschr 1999; 124: 584-8.
25. Gulhan M, Erturk A, Kurt B, et al: Diffuse panbronchiolitis observed in a white man in Turkey. Sarcoidosis Vase Diffuse Lung Dis 2000; 17: 292-6.
26. Claxton S, Markos J: A case of diffuse panbronchiolitis. Aust N Z J Med 2000; 30: 99-100.
27. Martinez JA, Guimaraes SM, Ferreira RG, Pereira CA: Diffuse panbronchiolitis in Latin America. Am J Med Sci 2000; 319: 183-5.
28. Souza R, Kairalla RA, Santos U de P, Takagaki TY, Capelozzi VL, Carvalho CR: Diffuse panbronchiolitis: an underdiagnosed disease? Study of 4 cases in Brazil. Rev Hosp Clin Fac Med Sao Paulo 2002; 57: 167-74.
29. Sandrini A, Balter MS, Chapman KR: Diffuse panbronchiolitis in a Caucasian man in Canada. Can Respir J 2003; 10: 449-51.
30. Poletti V, Chilosi M, Trisolini R, et al: Idiopathic bronchiolitis mimicking diffuse panbronchiolitis. Sarcoidosis Vase Diffuse Lung Dis 2003; 20: 62-8.
31. Tomlinson IPM, Bodmer WF: The HLA system and the analysis of multifactorial genetic disease. Trends Genet 1995; 11: 493-8.
32. Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F: Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1990; 141: 1459-62.
33. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T (eds): HLA 1991. Vol. 1. New York: Oxford University Press 1991: 1065-1220.
34. Keicho N, Tokunaga K, Nakata K, et al: Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis. Am J Respir Crit Care Med 1998; 158: 846-50.
35. Mimura G, Kida K, Matsuura N, et al: Immunogenetics of early-onset insulin-dependent diabetes mellitus among the Japanese: HLA, Gm, BF, GLO, and organ-specific autoantibodies: the J.D.S. study. Diabetes Res Clin Pract 1990; 8: 253-62.
36. Nakai Y, Wakisaba A, Aizawa M, Itakura K, Nakai H, Ohashi A: HLA and rheumatoid arthritis in the Japanese. Arthritis Rheum 1981; 24: 722-5.
37. Honda K, Hirayama K, Kichuki I, Nagato H, Tamai H, Sasazuki T: HLA and silicosis in Japan. N Engl J Med 1988; 319: 1610.
38. Park MH, Kim YW, Yoon HI, et al: Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Am J Respir Crit Care Med 1999; 159: 526-9.
39. Keicho N, Ohashi J, Tamiya G, et al: Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am J Hum Genet 2000; 66: 501-7.
40. Hoiby N: Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994; 49: 531-2.
41. Akai S, Okayama H, Shimura S, Tanno Y, Sasaki H, Takishima T: Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am Rev Respir Dis 1992; 146: 781-3.
42. Yoshimura K, Iizuka A, Anzai C, et al: Diffuse panbronchiolitis is closely associated with mutations of the CFTR gene. Am J Respir Crit Care Med 2000; 161: A77.
43. Homma S, Kawabata M, Kishi K, et al: Bronchiolitis in Kartagener's syndrome. Eur Respir J 1999; 14: 1332-9.
44. Pizzi S, Cazzato S, Bernardi F, Mantovani W, Cenacchi G: Clinico-pathological evaluation of ciliary dyskinesia: diagnostic role of electron microscopy. Ultrastruct Pathol 2003; 27: 243-52.
45. Amitani R, Tomioka H, Kurasawa T, Ishida T, Kuze F: Clinical and ultrastructural study on primary ciliary dyskinesia. Nihon Kyobu Shikkan Gakkai Zasshi 1990; 28: 300-7.
46. Azuma K, Keicho N, Furukawa H, Yabe T, Kudoh S: Prolonged survival of a bare lymphocyte syndrome type 1 patient with diffuse panbronchiolitis treated with erythromycin. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 312-3.
47. Furukawa H, Murata S, Yabe T, et al: Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest 1999; 103: 755-8.
48. Raghavan M: Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. J Clin Invest 1999; 103: 595-6.
49. Iwata M, Colby TV, Kitaichi M: Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations. Hum Pathol 1994; 25: 357-63.
50. Maeda M, Saiki S, Yamanaka A: Serial section analysis of the lesions in diffuse panbronchiolitis. Acta Pathol Jpn 1987; 37: 693-704.
51. Ryu JH, Myers JL, Swensen SJ: Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168: 1277-92.
52. Mimoto T, Uchida K, Sakuraba S, et al: A case of diffuse panbronchiolitis, performed an open lung biopsy after improvement with 6 years medication. Jpn J Thorac Dis 1991; 29: 893-9.
53. Sakito O, Kadota J, Kohno S, et al: Interleukin 1β, tumor necrosis factor-α and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 42-8.
54. Oishi K, Sonoda F, Kobayashi S, et al: Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62: 4145-52.
55. Oda H, Kadota J, Kohno S, Hara K: Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest 1995; 108: 116-22.
56. Hiratsuka T, Mukae H, Iiboshi H, et al: Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 2003; 58: 425-30.
57. Ichikawa Y, Koga H, Tanaka M, Nakamura M, Tokunaga N, Kaji M: Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis. Chest 1990; 98: 917-23.
58. Ninomiya H, Ichikawa Y, Koga H, Yano T, Oizumi K: Elastase activity in bronchoalveolar lavage fluid from patients with diffuse panbronchiolitis. Kansenshogaku Zasshi 1991; 65: 672-80.
59. Ichikawa Y, Ninomiya H, Koga H, et al: Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992; 146: 196-203.
60. Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994; 106: 1116-23.
61. Katoh S, Matsubara Y, Taniguchi H, et al: Characterization of CD44 expressed on alveolar macrophages in patients with diffuse panbronchiolitis. Clin Exp Immunol 2001; 126: 545-50.
62. Mukae H, Kadota J, Ashitani J, et al: Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis. Chest 1997; 112: 1615-21.
63. Sato A, Chida K, Iwata M, Hayakawa H: Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1992; 146: 473-8.
64. Fujii T, Kadota J, Mukae H, Kawakami K, Iida K, Kohno S: Gamma-delta T cells in BAL fluid of chronic lower respiratory tract infection. Chest 1997; 111: 1697-1701.
65. Mukac H, Kadota J, Kohno S, et al: Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995; 152: 613-8.
66. Kawakami K, Kadota J, Iida K, et al: Phenotypic characterization of T cells in broachoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells. Clin Exp Immunol 1997; 107: 410-6.
67. Todate A, Chida K, Suda T, et al: Increased numbers of dendritic cells in the bronchiolar tissues of diffuse panbronchiolitis. Am J Respir Crit Care Med 2000; 162: 148-53.
68. Nishimura K, Kitaichi M, Izumi T, Itoh H: Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings. Radiology 1992; 184: 779-85.
69. Akira M, Kitatani F, Lee YS, et al: Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology 1988; 168: 433-8.
70. Zompatori M, Poletti V, Rimondi MR, Battaglia M, Carvelli P, Maraldi F: Imaging of small airways disease, with emphasis on high resolution computed tomography. Monaldi Arch Chest Dis 1997; 52: 242-8.
71. Poletti V, Zompatori M, Cancellieri A: Clinical spectrum of adult chronic bronchiolitis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 183-96.
72. Nicholson AG, Colby TV, Wells AU: Histopathological approach to patterns of interstitial pneumonia in patients with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 10-7.
73. Mukae H, Hirota M, Kohno S, et al. Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 148: 744-51.
74. Nakano H, Ide H, Imada M, et al: Reduced nasal nitric oxide in diffuse panbronchiolitis. Am J Respir Crit Care Med 2000; 162: 2218-20.
75. Koyama H, Nishimura K, Mio T, Ikeda A, Sugiura N, Izumi T: Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis. Thorax 1994; 49: 540-4.
76. Tanimoto H: A review of the recent progress of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan. Antibiot Chemother 1991; 44: 94-8.
77. Nakata K: Revision of clinical guidelines for diffuse panbronchiolitis. Annual report on the study of diffuse lung disease in 1998. Grant-in Aid from the Ministry of Health and Welfare of Japan, Tokyo, Japan 1999: 109-11.
78. Tsuburai T, Ikehara K, Suzuki S, et al: Hypogammaglobulinemia associated with thymoma (Good syndrome) similar to diffuse panbronchiolitis. Nihon Kokyuki Gakkai Zasshi 2003; 41: 421-5.
79. Poletti V, Chilosi M, Zompatori M: Bronchiolitis. In: Gibson GJ, Geddes DM, Costabel U, Sterk PJ, Corrin B (eds): Respiratory Medicine. London: Elsevier Science 2003: 1526-41.
80. Fraser RS, Muller NL, Cohran N, Paré PD: Bronchiolitis. In: Fraser and Paré's Diagnosis of Diseases of the Chest. Philadelphia: WB Saunders Co, 1999: 2321-57.
81. Veraehakelen JA: Imaging of the small airways. In: Costabel U, Poletti V (Guest eds): Bronchiolar disorders. Semin Respir Crit Care Med, 2003; 5: 473-88.
82. Kudoh S, Koicho N: Diffuse panbronchiolitis. In: Costabel U, Poletti V (Guest eds): Bronchiolar disorders. Semin Respir Crit Care Med 2003; 5: 607-17.
83. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M: Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829-32.
84. Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N: The long term chemotherapy with erythromycin in chronic lower respiratory tract infections-second report: including cases with Pseudomonas infections. Kansenshogaku Zasshi 1986; 60: 45-50.
85. Yamamoto M: A double-blind placebo-controlled study on the therapeutic effect of erythromycin on DPB. Annual Report on the study of diffuse lung disease in 1990. Grant-in Aid from the Ministry of Health and Welfare of Japan, Tokyo, Japan 1991: 18-20.
86. Nagai H, Shishido H, Yoneda R, Yamagichi E, Tamura A, Kurashima A: Long-term low dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58: 145-9.
87. Fujii T, Kadota J, Kawakami K, et al: Long-term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995; 50: 1246-52.
88. Baz MA, Kussin PS, Van Trigt P, Davis RD, Roggli VL, Tapson VF: Recurrence of diffuse panbronchiolitis after lung transplantation. Am J Respir Crit Care Med 1995; 151: 895-8.
89. Tamaoki J, Takeyama K, Tagaya E, Konno K: Effect of clarithromycin on sputum production and its theological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39: 1688-90.
90. Shirai T, Sato A, Chida K: Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Intern Med 1995; 34: 469-74.
91. Kadota J, Mukae H, Ishii H, et al: Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003; 97: 844-50.
92. Nagai K, Taguchi Y, Kudoh S: Therapeutic guidelines for diffuse panbronchiolitis. Annual Report on the study of diffuse lung disease in 1999. Tokyo: Grant-in-Aid from the Ministry of Health and Welfare of Japan 2000: 111.
93. Jaffe A, Bush A: Anti-inflammatory effects of macrolides in lung disease. Pediatr. Pulmonol 2001; 31: 464-73.
94. Hoyt JC, Robbins RA: Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett 2001; 205: 1-7.
95. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y: In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 2003; 168: 581-7.
96. Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K: Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992; 5: 234-8.
97. Kondo M, Kanoh S, Tamaoki J, Shirakawa H, Miyazaki S, Nagai A: Erythromycin inhibits ATP-induced intracellular calcium responses in bovine tracheal epithelial cells. Am J Respir Cell Mol Biol 1998; 19: 799-804.
98. Zhao DM, Xue HH, Chida K, et al: Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol 2000; 27: L726-36.
99. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y: Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol 2003; 285: L847-53.
100. Rubin BK, Druce H, Ramirez OE, Plamer R: Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155: 2018-23.
101. Kadota J, Sakito O, Kohno S, et al: A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147: 153-9.
102. Wales D, Woodhead M: The anti-inflammatory effects of macrolides. Thorax 1995; 54 (suppl. 2): S58-S62
103. Yanagihara K, Kadoto J, Kohno S: Diffuse panbronchiolitis pathophysiology and treatment mechanisms. Int J Antimicrob Agents 2001, 18 (suppl. 1): 83-7.
104. Labro MT: Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998; 41 (suppl. B): 37-46.
105. Culic O, Erakovic V, Parnham MJ: Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209-29.
106. Miyajima M, Suga M, Nakagawa K, Ito K, Ando M: Effect of erythromycin on experimental extrinsic allergic alveolitis. Clin Exp Allergy 1999; 29: 253-61.
107. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ: Effect of erythromycin on Haemophilus infuenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995; 8: 1451-7.
108. Hand WL, Hand DL, King-Thompson NL: Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1990; 34: 863-70.
109. Oda H, Kadota J, Kohno S, Hara K: Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest 1995; 108: 116-22.
110. Hiratsuka T, Mukae H, Iboshi H, et al: Increased concentrations of human β-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 2003; 58: 425-30.
111. Desaki M, Takizawa H, Ohtoshi T, et al: Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000; 267: 124-8.
112. Iion Y, Toriyama M, Kudo Y, Natori Y, You A: Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol 1992; 267 (suppl.): 124-8.
113. Schultz MJ, Speelman P, Zaat S, van Deventer SJ, van der Poll T: Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob Agents Chemother 1998; 42: 1605-9.
114. Kawasaki S, Tikizawa H, Ohtoshi T, et al: Roxithromycin inhibits cytokine production by neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998; 42: 1499-1502.
115. Yamasawa H, Oshikawa K, Ohno S, Sugiyama Y: Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating GM-CSF release. Am J Respir Cell Mol Biol 2003; 30: 569-75.
116. Morikawa K, Oseko F, Morikawa S, Iwamoto K: Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lympocyte function in vitro. Antimicrob Agents Chemother 1994; 38: 2643-7.
117. Keicho N, Kudoh S, Yotsumoto H, Akagawa KS: Erythromycin promotes monocyte to macrophage differentiation. J Antibiol 1994; 47: 80-9.
118. Molinari G, Guzman CA, Pesce A, Schito GC: Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31: 681-8.
119. Kobayashi H: Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995; 99 (6A): 26S-30S.
120. Zalewska-Kaszubska J, Gorska D: Anti-inflammatory capabilities of macrolides. Pharmacol Res 2001; 44: 451-4.
121. Saiman L, Marshall BC, Mayer-Hamblett N, et al: Azithromycin in patients with cystic fibrosis clinically infected with Pseudomonas aeruginosa. JAMA 2003; 290: 1749-56.